logo

Are you experiencing hair loss due to alopecia areata - a condition where hair loss results from the immune system attacking the hair follicle? We are recruiting eligible participants for a new study investigating rezpegaldesleukin (also known as REZPEG), a targeted therapy that may help reverse hair loss in patients with alopecia areata (AA).

We are currently recruiting adult males (ages 18 to 60) and adult females (ages 18 to 70) with hair loss (severe to very severe) due to alopecia areata (AA) to participate in a clinical trial. The main purpose of this study is to evaluate how safe and effective the investigational drug REZPEG is in participants experiencing hair loss from AA.

The study consists of a subcutaneous injection (an injection under the skin) given every 2 weeks at the clinic. Different doses of REZPEG will be compared to placebo. This is a randomized, double-blind study, which means that whether you receive REZPEG or placebo will be decided by chance and neither you nor your study physician will know whether you are receiving the active drug. Before you start the treatment period, you will be assigned (like flipping a coin) by a computer to 1 of 3 groups. You will be evaluated throughout the study by a clinician and will be asked to complete questionnaires about your health throughout the study. Study treatment will be administered by the study staff. 

Participation will last up to 18 months, including up to 35 days for screening, up to 1 year of treatment, and approximately 6-months of follow up. Visits will typically take 1-2 hours, though some may take up to 3 hours.

Blood and/or urine samples will be collected from all participants at some of the visits.

An electrocardiogram to check heart health will be taken up to 3 times during the study.

Medical photography of the full head (including the face) will be taken to evaluate extent of hair loss and any regrowth.

Reimbursement for time and travel may be available. There will be no cost to you for taking part in this study, and you will be provided with all study medication, examinations, and medical care related to the study.

To see if you are eligible for the study, please complete the online study-specific questionnaire.

 


Visits
Drug administered on which days
Total
Length
Procedures
Study Length
Days
Drug administered on which days Every 2 weeks for up to 1 year
Total
Total number of visits Up to 24
Length
Visit length (including screening) Usually 1-2 hours, through some may be up to 3 hours
Procedures
(Visits could consist of any of the following, but do not occur on every visit.) Questionnaires, medical photography of the full head (including the face), blood and urine samples.
Study Length
Total study length Up to 18 months
Summary
We are currently recruiting adult males (ages 18 to 60) and adult females (ages 18 to 70) with severe hair loss (impacting at least half of the scalp) due to alopecia areata (AA) to participate in a clinical trial. The main purpose of this study is to evaluate how safe and effective the investigational drug rezpegaldesleukin (REZPEG) is in participants experiencing hair loss from AA. In this study, patients with other types of alopecia, such as traction alopecia or androgenic alopecia (pattern hair loss), would not be eligible. If you are unaware about what type of alopecia you have, a study doctor may be able to help determine that as part of being considered for the study.
Condition
Alopecia areata
Treatment
Rezpegaldesleukin
Rectangle 191

Are you a researcher or representative of a clinical site?

Join our network of clinical sites and be at the forefront of innovation in clinical research.